

PHARMACEUTICAL 2023

REGENERON



REGENERON PHARMACEUTICALS INC. Rank 49 of 446







The relative strengths and weaknesses of REGENERON PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of REGENERON PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 95% points. The greatest weakness of REGENERON PHARMACEUTICALS INC. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 8.5% points.

The company's Economic Capital Ratio, given in the ranking table, is 242%, being 199% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	15,884,100
Cost of Goods Sold	0
Intangible Assets	915,500
Liabilities, Current	3,141,300
Liabilities, Non-Current	2,689,200
Other Assets	12,414,900
Other Compr. Net Income	-212,600
Other Expenses	2,246,000
Other Liabilities	720,000
Other Net Income	119,900
Other Revenues	12,172,900
Property and Equipment	0
Research and Development	3,592,500
Selling, General and Administrative Expense	2,115,900

Output Variable	Value in 1000 USD
Assets	29,214,500
Liabilities	6,550,500
Expenses	7,954,400
Revenues	12,172,900
Stockholders Equity	22,664,000
Net Income	4,338,400
Comprehensive Net Income	4,232,100
Economic Capital Ratio	242%

